Detalhe da pesquisa
1.
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
N Engl J Med
; 389(8): 710-721, 2023 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611121
2.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 42(1): 145-159, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324085
3.
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Cancer
; 129(8): 1195-1204, 2023 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748723
4.
Patient and provider factors associated with colorectal cancer screening among average risk health plan enrollees in the US, 2015-2018.
BMC Health Serv Res
; 23(1): 550, 2023 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237408
5.
Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada.
Int J Cancer
; 150(8): 1244-1254, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34843106
6.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1103-1115, 2019 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30779531
7.
Assessing the Effects of Geniculate Artery Embolization in a Nonsurgical Animal Model of Osteoarthritis.
J Vasc Interv Radiol
; 33(9): 1073-1082.e2, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35659574
8.
Adherence to fecal immunochemical test screening among adults at average risk for colorectal cancer.
Int J Colorectal Dis
; 37(3): 719-721, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34729622
9.
Analysis of Geographic and Environmental Factors and Their Association with Cutaneous Melanoma Incidence in Canada.
Dermatology
; 238(6): 1006-1017, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679838
10.
Incident colorectal cancer screening and associated healthcare resource utilization and Medicare cost among Medicare beneficiaries aged 66-75 years in 2016-2018.
BMC Health Serv Res
; 22(1): 1228, 2022 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36192728
11.
A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens.
Int J Mol Sci
; 23(8)2022 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35457260
12.
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Invest New Drugs
; 39(6): 1587-1597, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180037
13.
Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort.
Int J Colorectal Dis
; 36(11): 2471-2480, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019124
14.
Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.
Proc Natl Acad Sci U S A
; 115(10): E2202-E2209, 2018 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463754
15.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol
; 21(10): 1353-1365, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32919526
16.
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Invest New Drugs
; 38(4): 1156-1165, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31734832
17.
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Nature
; 511(7507): 90-3, 2014 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24870236
18.
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.
Int J Mol Sci
; 21(11)2020 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32517051
19.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 42(3): 340-341, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38767685
20.
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Breast Cancer Res
; 19(1): 54, 2017 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28464908